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Abstract
Background: APMCF1 is a novel human gene first cloned from apoptotic MCF-7 cells. Our
previous study found ectogenic APMCF1 could induce G1 arrest in hepatocarcinoma cell line
HHCC. In order to search its broad expression profile for further understanding of its mechanism
in tumor, we investigated a subcellular location of APMCF1 and performed an
immunohistochemistry study including various tumor and normal tissues. Discovery from the
expression characterization of AMPCF1 may have applicability in the analysis of its biological
function in tumor.
Methods: We investigated subcellular localization of APMCF1 by transient transfection in green
monkey kidney epithelial cells (COS-7) with a fusion protein vector pEGFP-APMCF1 and detected
expression profile in a broad range of normal and malignant human tissues via tissue microarray
(TMA) by immunohistochemistry with polyclonal antibody first produced in our laboratory.
Results: EGFP-APMCF1 was generally localized in the cytoplasm of COS-7 cell. Positive staining
of APMCF1 was found in liver, lung, breast, colon, stomach, esophagus and testis, exhibited a
ubiquitous expression pattern while its expression was up-regulated in tumor tissues compared
with corresponding normal tissues. Normal brain neuron cells also showed expression of APMCF1,
but negative in gliocyte cells and glioma. Both the normal and tumor tissues of ovary were absent
of APMCF1 expression. Positive immunostaining for APMCF1 with large samples in liver, colon,
esophagus, lung and breast carcinomas were 96% (51/53), 80% (44/55), 57% (30/53), 58% (33/57)
and 34% (16/47) respectively.
Conclusion: These results revealed a cytoplastic expression pattern of APMCF1 and up-regulated
in tumour tissues suggesting APMCF1 may have potential relationship with oncogenesis. The data
presented should serve as a useful reference for further studies of APMCF1 functions in
tumorigenesis and might provide a potential anti-tumor target.
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Background
The APMCF1 gene was first isolated from the cDNA bank
of breast carcinoma cell line MCF-7 cells treated with all-
trans retinoic acid (ATRA) by an improved PCR-based
subtractive hybridization strategy [1,2]. The cDNA is
1,745 bp in full length and is located in chromosome
3q23–24. The predicted protein of human APMCF1 con-
tains a small GTP-protein (G protein) domain which sug-
gests that APMCF1 is a novel member of the small G-
protein superfamily [3,4]. More interesting is that
APMCF1 and rat homolog named as signal recognition
particle receptor β (SRβ) are of 271 and 269 amino acids,
respectively, and are highly homologous (89% amino
acid identity). Further analysis shows it also shares signif-
icant homology to the SRβ proteins of species such as Sac-
charomyces, C. elegan, Drosophila, and indicates that
APMCF1 is human SRβ, a member of small G protein reg-
ulating intracellular vesicle trafficking, as well as a well-
conserved protein [3-5].
Moreover, as a potential small G-protein, APMCF1 may
play a key role in diverse cellular and developmental
events like other identified small G-protein family mem-
bers (i.e. the Ras and Rho), including differentiation, cell
division, vesicle transport, nuclear assembly, and control
of the cytoskeleton [6].
Currently, few literatures about the function study of this
gene have been reported, especially in tumor. In order to
learn more about the expression pattern and potential
biological function of APMCF1 in other tumors, we
detected APMCF1 subcellular localization and expression
profile in a broad range of normal and malignant human
tissues in this study.
Methods
Reagents
pGEM-APMCF1 and pEGFP-C1 have been characterized
[3]. Restriction enzymes Hind-Ø, Sal I polymerase were
purchased from Takara (Dalian, China). DMEM medium
and FBS were obtained from Gibco-BRL (Gaithersburg,
MD, USA). 1 kb Plus ladder, G418 and lipofectmin2000
were purchased from Invitrogen (Carlsbad, CA, USA).
Samples
Six TMAs with one containing nine kinds of important
human organs including their malignant tumor, tumor-
adjacent tissues and normal tissues, and the others con-
taining five kinds of frequent human epithelia carcinoma
were involved in this study (Cybrdi Inc., Shaanxi, China).
Table 1 and 2 listed detailed information of the tissues
presented on the slides.
Cell culture
Immortalized monkey kidney COS-7 cells were stocked in
our lab. Cells were cultured in DMEM medium containing
10% fetal bovine serum, 50 IU/ml penicillin and 50 μg/
ml gentamycin at 37°C under an atmosphere of 5% CO2.
Plasmids
The entire APMCF1 coding region was amplified by PCR,
using upstream and downstream primers which introduce
a Hind III and Sal I site respectively according to the con-
junct sequence. APMCF1 PCR primers were designed as
follows: sense 5' ATAAGCTTCCATGGCTTCCG 3'; anti-
sense 5' ACGCGTCGACCTGCCTCTCAGGCAAT 3'.
pGEM-APMCF1 constructed by our lab previously [3] was
used as templates for PCR amplification. PCR products
were digested with Hind III and Sal I, and subcloned into
pEGFP-C1, resulting in pEGFP-C1-APMCF1 to express
APMCF1 protein fused to GFP. The recombinant plasmid
Table 1: Expression of APMCF1 in normal and malignant human 
tissues
Tissue type Sample size Score
Liver
carcinoma tissues 2 +++/+++
tumor-adjacent tissues 2 ++/++
normal tissues 2 ++/+
Lung
carcinoma tissues 2 +++/+++
tumor-adjacent tissues 2 +/+
normal tissues 2 +/+
Breast
carcinoma tissues 2 ++/+++
tumor-adjacent tissues 2 ++/+
normal tissues 2 +/-
Stomach
carcinoma tissues 2 ++/++
tumor-adjacent tissues 2 +/-
normal tissues 2 -/-
Colon
carcinoma tissues 2 +++/+++
tumor-adjacent tissues 2 +/+
normal tissues 2 ++/-
Ovary
carcinoma tissues 2 -/-
tumor-adjacent tissues 2 -/-
normal tissues 2 -/-
Esophagus
carcinoma tissues 2 +++/+++
tumor-adjacent tissues 2 ++/+++
normal tissues 2 +/+
Brain
glioma tissues 2 -/-
tumor-adjacent tissues 2 +/-
normal tissues 2 +/+
Testis
seminoma tissues 2 ++/+
tumor-adjacent tissues 2 +/-
normal tissues 2 +/-
As indicated in the Methods section, APMCF1 immunolabeling was 
scored as follows: weak immunolabeling (+), moderate 
immunolabeling (++), strong immunolabeling (+++), and no 
immunolabeling (-).Journal of Experimental & Clinical Cancer Research 2009, 28:111 http://www.jeccr.com/content/28/1/111
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was confirmed by Hind III and Sal I digestion and
sequencing.
Gene transfection
COS-7 cells which were seeded on glass cover-slips in 6
cm plates were cultured in DMEM medium containing
10% fetal bovine serum, and transiently transfected with
the plasmid at 50–70% confluence using
lipofectmin2000 reagent according to manufacturer
instructions. Cover-slips were taken out of six-well plates
after transfecting 24 h to use in the detection of expression
with recombinant APMCF1 protein. As a control we used
the pEGFP-C1 vector producing GFP protein.
Immunohistochemical Analysis
Tissue sections on microscopic slides were processed
through a graded series of alcohols and rehydrated in dis-
tilled water. Heat-induced antigen retrieval was per-
formed by hydrated autoclaving in citrate buffer (10
mmol/L concentration, pH 6.0) for 5 min. To minimize
non-specific background reactivity, tissue sections were
incubated with normal goat serum for 10 min. The slides
were cooled to room temperature for 30 min to complete
antigen unmasking, and standard indirect biotin-avidin
immunohistochemical analysis was performed to evalu-
ate APMCF1 protein expression using a polyclonal anti-
APMCF1 antibody (1:100 diluted) produced by our lab
previously [3]. Incubation with non-immune rabbit
serum and antibody blocked with purified APMCF1 pro-
tein served as a negative control.
Protein expression was scored by two observers as: absent
(-); weakly positive (+), < 10% cells showed positive stain-
ing; moderately positive (++), 10–50% cells showed pos-
itive staining; or strongly positive (+++), > 50% cells
showed positive staining.
Results
Subcellular localization of APMCF1 protein
For direct visualization of the cellular location of
APMCF1, the corresponding cDNAs were cloned in frame
with enhanced green fluorescent protein (EGFP) in the
mammalian expression vector pEGFP-C1, followed by
transient transfection into green monkey kidney epithelial
cells (COS-7). Typical patterns are shown in Figure 1. In
singly transfected cells, fluorescence was dispersed
throughout the cytoplasm.
Expression of APMCF1 in normal and malignant human 
tissues
Brown labeling represented the presence of APMCF1. The
relative intensity was scored from (-) to (+++). Specific
cytoplasmic staining was observed in the majority of pos-
itive stained cells, suggesting that APMCF1 was a cytoplas-
mic protein.
Generally, APMCF1 was detected in the parenchymal cells
of liver, lung, breast, colon, stomach, esophagus and tes-
tis, including the malignant tumor, tumor-adjacent tis-
sues and normal tissues. Normal brain neuron cells also
showed expression of APMCF1, but no detectable labeling
was observed in brain gliocyte cells and glioma. Both the
normal and tumor tissues of ovary were absent of
APMCF1 expression. Representative photomicrographs
are presented in Figure 2. A high expression level of
APMCF1 was found in most of human carcinomas com-
pared with that in their normal tissues (Table 1).
We also detect the specific expression pattern of APMCF1
in several common carcinomas including liver, colon,
esophagus, lung and breast carcinomas in a large sample
(Table 2). The positive ratios of APMCF1 in liver, colon,
esophagus, lung and breast carcinomas were 96%, 80%,
57%, 58% and 34% respectively.
Discussion
Small GTP-binding proteins (G proteins) are monomeric
G proteins with GTPase structure in amino acid sequence
structure and molecular masses of 20–40 kDa, currently
existing in eukaryotes from yeast to human and contain-
ing more than 100 members. Based on both their
sequence homology and function, they have been subdi-
vided into at least six families: Ras, Rho, Rab, Sar1/Arf,
Ran, and Rad/Gem [7,8]. They regulate a wide variety of
cell functions in response to diverse stimuli, such as cell
growth, apoptosis, lipid metabolism, cytoarchitecture,
membrane trafficking, and transcriptional regulation [9-
12]. However, uncontrolled activation of these multifunc-
tional proteins (i.e. point mutations or overexpression)
cause them insensitive to regulatory signals, leading to
Table 2: Expression of APMCF1 in human carcinomas
Tissue type Sample size Positive Positive frequency (%)
Colon carcinoma 55 44 80
Esophageal carcinoma 53 30 57
Lung carcinoma 57 33 58
Hepatic carcinoma 53 51 96
Breast carcinoma 47 16 34Journal of Experimental & Clinical Cancer Research 2009, 28:111 http://www.jeccr.com/content/28/1/111
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uncontrolled proliferation, enhanced angiogenesis, inhi-
bition of apoptosis, and genetic instability, all of which
result in tumor development [12-14]. Their cellular onco-
genes were then identified, and their mutations were fur-
thermore found in some human carcinomas [15-17].
The predicted protein of APMCF1 contained a GTPase
domain closely related to ADP-ribosylation factor family
(ARF) and Sar1p-like members of the Ras-family of small
GTPases, suggesting it was a new member of small GTP-
binding proteins and also a human homolog of SRβ [18].
The SR is a heterodimeric complex assembled by the two
GTPases SRα and SRβ [5]. The eukaryotic signal recogni-
tion particle (SRP) and its receptor (SR) play a central role
in co-translational targeting of secretory and membrane
proteins to the endoplasmic reticulum (ER). In eukaryo-
tes, this process is tightly controlled by the concerted
action of three G proteins, the 54-kD subunit of SRP, SRα
and SRβ [19-22]. All SRβ members in species other than
human are cytoplasmic proteins. The subcellular location
in present study based on APMCF1-GFP fusion protein
identified that APMCF1 has a cytosol distribution pattern
which also concoined it was a human homolog of SRβ.
There is little information about the function of AMPCF1
so far. As a human homolog of SRβ, APMCF1 might be
involved in the targeting of nascent polypeptide chains to
the protein translocation machinery in the endoplasmic
reticulum membrane similar to the effects of SRβ in rat
and saccharomyces. In the present study, most tissues
examined such as: brain, liver, lung, breast, colon, stom-
ach, esophagus and testis showed a little nonhomogene-
ous expression of APMCF1. As a matter of fact, protein
translocation across and insertion into membranes in
cells are essential to all life forms, which might elucidate
the results of a wide range expression pattern of APMCF1
in different normal human tissues.
On the other hand, in our preliminary study, APMCF1
was cloned as a novel apoptosis related gene whose tran-
scripts were up regulated in apoptotic breast carcinoma
MCF-7 cells and protein level was elevated in colon carci-
noma [2,3]. Furthermore, ectogenic expression of
APMCF1 could induce inhibition of HHCC growth.
Results of cell cycle gene chips analysis showed up-regula-
tion of p21 expression and down-regulation of TIMP3 in
HHCC cells expressing ectogenic APMCF1, indicating that
APMCF1 participates at least partially in cell cycle regula-
tion through regulating genes such as p21 and TIMP3 [4].
The IHC study reported here showed its expression was
up-regulated in the carcinoma tissues of liver, colon,
esophagus, lung and breast carcinomas compared with
their corresponding normal tissues, and the positive ratios
of APMCF1 in liver, colon, esophagus, lung and breast car-
cinomas with a large samples were 96%, 80%, 57%, 58%
and 34% respectively. These results together suggested
APMCF1 might have a relationship with the cell growth,
apoptosis of tumor cells or oncogenesis.
A recent study in microarrays analysis from Andrew Ber-
chuck showed differences in survival of advanced ovarian
cancers were reflected by distinct patterns of gene expres-
sion. APMCF1 together with T-cell differentiation protein
(MAL), diphosphoinositol polyphosphate phosphohy-
drolase type2 (NUDT4), plakophilin 4 (PKP4), and signal
sequence receptor (SSR1) were the top five genes
involved, which were highly up-regulated in short-term
survivors compared with long-term survivors and early-
stage cases of ovarian cancers [23]. Many of the genes that
were critical components of the patterns that discrimi-
nated between long-term and short-term survivors are
known to affect the virulence of the malignant phenotype.
Such as the MAL protein, a component of the protein
machinery for apical transport in epithelial polarized cells
and a component of membrane rafts which are micro-
domains that play a central role in signal transduction act-
ing as a scaffold in which molecules of signal transduction
pathways can interact [24,25], has been shown expressed
in ovarian cancers, most notably clear cell and serous can-
cers [26]. Thus we presume APMCF1 might be a critical
factor in ovarian cancers though its expression was absent
in the 2 cases of malignant ovarian tissues we detected.
The additional independent expression study of APMCF1
is needed with large sample of ovarian cancers.
From the view of molecular structure, thus, as closely
related to small G-protein superfamily, APMCF1 deserves
further investigation whether it also has the function of
Subcellular localization of the EGFP-APMCF1 fusion protein Figure 1
Subcellular localization of the EGFP-APMCF1 fusion 
protein. COS-7 cells were transfected with pEGFP-C1-
APMCF1 or pEGFP-C1 vector. Twenty-four hours after 
transfection, subcellular localization of EGFP-APMCF1 fusion 
proteins was examined by direct fluorescent microscopy. (A) 
green fluorescence was seen in the cell cytoplasm of COS-7 
cells transfected with pEGFP-C1-APMCF1; (B) green fluores-
cence was seen in the cell nuclei and cytoplasm of COS-7 
cells transfected with pEGFP-C1.Journal of Experimental & Clinical Cancer Research 2009, 28:111 http://www.jeccr.com/content/28/1/111
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regulating cell proliferation, apoptosis, tumorigenesis and
metastasis. The present study has established foundation
for new insight into the possible biological function of
APMCF1 in tumor development and may represent an
appealing potential therapeutic target in some tumors
with high expression pattern of APMCF1.
Conclusion
Our studies revealed a cytoplastic expression pattern of
APMCF1 and up-regulation in many epithelium tumors
suggesting APMCF1 may have potential relationship with
oncogenesis. The data presented should serve as a useful
reference for further studies of APMCF1 in tumorigenesis
and provide a potential anti-tumor target.
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Expression of APMCF1 in normal and malignant human tissues Figure 2
Expression of APMCF1 in normal and malignant human tissues. Expression of APMCF1 in normal and malignant 
human tissues was detected by immunohistochemistry. (A) esophagus carcinoma; (B) colon carcinoma; (C) gastric carcinoma; 
(D) liver carcinoma; (E) breast carcinoma; (F) lung carcinoma; (G) testis seminoma; (H) brain; (I) gastric mucosa. Bar = 50 μm.Publish with BioMed Central    and   every 
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